140 related articles for article (PubMed ID: 36477777)
21. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.
Hu D; Ma D; Zhang ZJ; Zhang Y; Huang K; Li X
Front Endocrinol (Lausanne); 2023; 14():1103429. PubMed ID: 36742399
[TBL] [Abstract][Full Text] [Related]
22. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
23. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
25. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
[TBL] [Abstract][Full Text] [Related]
26. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
Cuff J; Longacre TA
Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
[TBL] [Abstract][Full Text] [Related]
27. Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
Ceppi L; Grassi T; Galli F; Buda A; Aletti G; Lissoni AA; Adorni M; Garbi A; Colombo N; Bonazzi C; Landoni F; Fruscio R
Gynecol Oncol; 2021 Jan; 160(1):64-70. PubMed ID: 33077259
[TBL] [Abstract][Full Text] [Related]
28. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
29. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
30. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort.
Tang H; Liu Y; Wang X; Guan L; Chen W; Jiang H; Lu Y
Medicine (Baltimore); 2018 May; 97(21):e10881. PubMed ID: 29794794
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
32. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
33. Development and external validation of nomograms for predicting individual survival in patients with ovarian clear cell carcinoma.
Liu X; Lu H; Zhou Y; Long X; Li Q; Zhuang G; Yin X; Di W
Cancer Med; 2023 May; 12(10):11385-11395. PubMed ID: 36971044
[TBL] [Abstract][Full Text] [Related]
34. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study.
Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L
Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932
[TBL] [Abstract][Full Text] [Related]
35. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma.
Tammela J; Geisler JP; Eskew PN; Geisler HE
Eur J Gynaecol Oncol; 1998; 19(5):438-40. PubMed ID: 9863906
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
38. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
39. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
[TBL] [Abstract][Full Text] [Related]
40. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
